Vol 18, No 4 (2022)
Review paper
Published online: 2022-06-20
Page views 4158
Article views/downloads 425
Get Citation

Connect on Social Media

Connect on Social Media

Epidemiological features and changes in the occurrence of infectious diseases in Poland from 2015 to 2020 in the context of the emerging novel SARS-CoV-2 (COVID-19) pandemic

Aneta Mela1, Elżbieta Rdzanek1, Łukasz A. Poniatowski12, Janusz Jaroszynski3, Tomasz Kalicki4, Monika M. Dutka5, Maciej Furman6, Anna Czajka7, Marzena Furtak-Niczyporuk8, Monika Wojciechowska9, Justyna E. Król-Całkowska10, Bartłomiej Drop11, Katarzyna Drop12, Maciej Krzakowski13, Magdalena Sakowicz14, Bartosz Grucza15, Joanna Cygler15, Beata Jagielska16
Oncol Clin Pract 2022;18(4):247-256.

Abstract

Introduction. The novel emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global public health concern. The ongoing pandemic outbreak in Poland makes a great impact on the diagnosis and treatment of other conditions including cancer and non-neoplastic diseases such as other infectious diseases. 

Research design. This study aimed to analyze trends in morbidity of selected infectious diseases in Poland over the last 6 years and assess the impact of the SARS-CoV-2 (COVID-19) pandemic on the incidence of other infectious diseases from January 1, 2020, to December 31, 2020, compared to the same period in 2019. 

Results. No clear trend in the total number of cases of infectious diseases in Poland in the years 2015–2019 was observed. During the period from January 1, 2020 to December 31, 2020, a total of 1 273 155 SARS-CoV-2 infections were recorded in Poland; they represented the second most common disease entity in the analyzed period (after flu and suspected flu). At the same time, there was a decrease in morbidity for almost all disease entities for which at least one case had been reported in 2019. The mean hospitalization rate for COVID-19 amounted to 250.2 cases per 100 000 inhabitants. 

Conclusions. The lack of a clear trend in data for the years 2015–2019 makes it difficult to measure the impact of COVID-19 disease on the occurrence of other infectious diseases in Poland. The latest data indicate a significant reduction in the number of cases reported in 2020 vs. 2019. The question remains, whether this reduction results from limitations in interpersonal contacts forced by the SARS-CoV-2 pandemic, or is it a matter of underreporting of other diseases.

Article available in PDF format

Purchase Subscription

References

  1. Zhai P, Ding Y, Wu X, et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020; 55(5): 105955.
  2. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020; 92(4): 401–402.
  3. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109: 102433.
  4. Wu D, Wu T, Liu Q, et al. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis. 2020; 94: 44–48.
  5. Jin YH, Zhan QY, Peng ZY, et al. Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM), Chinese Research Hospital Association (CRHA), , for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020; 7(1): 4.
  6. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020; 14(1): 69–71.
  7. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011; 81: 85–164.
  8. Yang D, Leibowitz JL. The structure and functions of coronavirus genomic 3' and 5' ends. Virus Res. 2015; 206: 120–133.
  9. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20): 1967–1976.
  10. Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012; 367(19): 1814–1820.
  11. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17(3): 181–192.
  12. Rodriguez-Morales AJ, Rodriguez-Morales AG, Méndez CA, et al. Tracing New Clinical Manifestations in Patients with COVID-19 in Chile and Its Potential Relationship with the SARS-CoV-2 Divergence. Curr Trop Med Rep. 2020; 7(3): 75–78.
  13. Wang X, Fang X, Cai Z, et al. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis. Research (Wash D C). 2020; 2020: 2402961.
  14. Guan WJ, Ni ZY, Hu Yu, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18): 1708–1720.
  15. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506.
  16. Wang D, Hu Bo, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061–1069.
  17. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25(3).
  18. Jin YH, Zhan QY, Peng ZY, et al. Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM), Chinese Research Hospital Association (CRHA), , for the Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care (CPAM). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020; 7(1): 4.
  19. Central Statistical Office. https://stat.gov.pl/obszary-tematyczne/ludnosc/ludnosc/powierzchnia-i-ludnosc-w-przekroju-terytorialnym-w-2020-roku,7,17.html (9.05.2021).
  20. Similarities and differences – COVID-19 and influenza. Pan American Health Organisation. https://www.paho.org/en/news/25-3-2020-similarities-and-differences-covid-19-and-influenza (9.06.2020).
  21. https://www.cdc.gov/flu/about/burden/preliminary-in-season-estimates.htm (9.06.2020).
  22. https://coronavirus.jhu.edu/map.html (10.06.2020).
  23. Budd A, Blanton L, Grohskopf L. Manual for the Surveillance of Vaccine-Preventable Diseases. Chapter 6. Influenza. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt06-influenza.html (24.06.2020).
  24. Richterich P. Severe underestimation of COVID-19 case numbers: effect of epidemic growth rate and test restrictions. 2020.
  25. SARS Basic Fact Sheet. https://www.cdc.gov/sars/about/fs-sars.html (9.06.2020).
  26. Incidence of selected infectious diseases in Poland from 1 January to 30 April 2019 and in the comparable period of 2018 and Incidence of selected infectious diseases in Poland from January 1 to April 30, 2020. and in the comparable period of 2019. http://wwwold.pzh.gov.pl/oldpage/epimeld/2020/INF_20_04B.pdf (20.06.2020).
  27. Lau H, Khosrawipour V, Kocbach P, et al. Internationally lost COVID-19 cases. Journal of Microbiology, Immunology and Infection. 2020; 53(3): 454–458.
  28. Koronawirus. Lista szpitali. https://www.gov.pl/web/koronawirus/lista-szpitali (9.06.2020).
  29. Vandoros S. Excess mortality during the Covid-19 pandemic: Early evidence from England and Wales. Soc Sci Med. 2020; 258: 113101.
  30. Beyond containment: Health systems responses to COVID-19 in the OECD. http://www.oecd.org/coronavirus/policy-responses/beyond-containment-health-systems-responses-to-covid-19-in-the-oecd-6ab740c0/ (9.06.2020).
  31. Health System Policy Monitor. WHO Europe Region. https://www.covid19healthsystem.org/countries/unitedkingdom/livinghit.aspx?Section=4.1%20Health%20financing&Type=Section (9.06.2020).
  32. Fundacja MY PACJENCI. Pacjenci w pandemii – raport. https://mypacjenci.org/pacjenci-w-pandemii/ (9.06.2020).
  33. Wielu pacjentów boi się zgłaszać na planowe zabiegi. https://www.mp.pl/pacjent/choroby-zakazne/koronawirus/koronawirus-aktualnosci/238834,wielu-pacjentow-boi-sie-zglaszac-na-planowe-zabiegi (9.06.2020).
  34. Próby przeczekania choroby w dobie pandemii to bardzo niepokojące zjawisko. https://www.rynekzdrowia.pl/Neurologia/Proby-przeczekania-choroby-w-dobie-pandemii-to-bardzo-niepokojace-zjawisko,207338,208.html (9.06.2020).
  35. Amador M, Matias-Guiu X, Sancho-Pardo G, et al. Impact of the COVID-19 pandemic on the care of cancer patients in Spain. ESMO Open. 2021; 6(3): 100157.
  36. Beltran-Aroca CM, Ruiz-Montero R, Llergo-Muñoz A, et al. Impact of the COVID-19 Pandemic on Palliative Care in Cancer Patients in Spain. Int J Environ Res Public Health. 2021; 18(22).
  37. Rodriguez GM, Ferguson JM, Kurian A, et al. The Impact of COVID-19 on Patients With Cancer: A National Study of Patient Experiences. Am J Clin Oncol. 2021; 44(11): 580–587.
  38. Kasiukiewicz A, Wojszel ZB. Assessment of Referrals and Hospitalizations in the Hospital Transformed into COVID-19 Facility in Poland during the "Spring Wave" of the Epidemic in 2020-A Cross-Sectional Study. Int J Environ Res Public Health. 2021; 18(13).
  39. https://ihe.se/en/publications/ihe-report/.
  40. State of lung cancer 2021. https://www.lung.org/getmedia/ba972351-ddc5-46b2-8e0d-028002d16c72/solc-2021-print-report-final.pdf.
  41. https://www.gov.pl/web/zdrowie/obwieoszenia-ministra-zdrowia-lista-lekow-refundowani.